CureVac withdraws vaccine from Ema approval process and focuses on second generation mRna

CureVac announces the decision to withdraw its first generation Covid vaccine candidate (CVnCoV) from the current approval process underway at the European Drug Agency Ema. Reason for the decision: The German company will focus on the development of the second generation mRNA vaccine candidates it is working on in collaboration with the UK’s GSK. The decision – explains CureVac – is also aligned with the evolving dynamics of the response to the pandemic: in fact, there is a greater need for differentiated vaccines to address a situation in which the Sars-CoV-2 virus will be endemic. As a direct consequence of this choice announced today, CureVac also informs that “the current advance purchase agreement with the European Commission, which was based on the use of the candidate CVnCoV vaccine” to address the needs of the acute phase of the pandemic, will cease. However, the company is evaluating the possibility of leveraging CVnCoV commitments for second-generation vaccine candidates.